Hector Ortega MD, ScD

Hector is an accomplished allergist, immunologist, and researcher who brings more than 25 years of experience in strategic clinical development and medical affairs oversight to Nexstone Immunology. Prior to joining Nexstone Immunology, he was Vice President of Clinical Development at Gossamer Bio. Additionally, he has held a number of roles at GlaxoSmithKline including Medical Expert and Senior Medical Director of Clinical Development. Under his leadership, he brought Nucala to market as a first-in-class anti-IL5 treatment for eosinophilic asthma.

Hector has also served in leadership roles in clinical development at Roche/Genentech supporting the lebrikizumab (anti-IL-13) and Xolair (anti-IgE) programs. The recipient of numerous awards, he received the 2018 American Thoracic Society Research and Innovation and Translation Achievement Award in recognition of outstanding contributions to the advancement of respiratory research.